The Latest News
TriSalus Life Sciences’ Pressure-Enabled Drug Delivery (PEDD) Significantly Increased Therapeutic Effect of Anti-CEA CAR-T in Pancreatic Cancer Patients with Liver Metastases>
- PEDD overpowers intratumoral high pressure, significantly increasing CAR-T into solid tumors
- Median overall survival (OS) 8.3 months and mean OS 9.8 months vs. 3 to 6 months standard of care
- Two of four stage IV patients who failed systemic chemotherapy showed metabolic complete response (CR); no visible liver metastases on PET
Developing investory management solutions to improve manufacturing profitability and streamline operations.
SupplySystem IS Leverages Advanced Technologies to Deliver a Competitive Advantage
Leadership appointment supports strategic shift to build oncology drug delivery company
Report contributors agreed gammaCore was highly innovative, may be more effective than standard of care alone, and has the potential to save money through the NHS by reducing the cost of treating cluster headache.
Makers of the rapidly growing AVISE CTD test expands portfolio of patented CB-CAPs blood tests
VERASENSE is transforming primary and revision total knee replacement for surgeons and patients across the globe.
Leading immunology laboratory continues strides with first ever economic impact data for AVISE Lupus
Alphatec Accelerates Organic Innovation Machine With Addition Of Key Senior Leadership And Expansion Of Market>
Mark Ojeda to lead Cervical and Biologics
Alphatec's OsseoScrew® System received 510(k) clearance from the U.S. Food & Drug Administration (
New company name better represents contribution to patient care
Exagen, Maker of AVISE Testing, Announces First Blood Test for Anti-CarP, a Breakthrough Biomarker for Rheumatoid Arthritis>
Novel test now available to aid in detection and management of widespread debilitating condition
SupplySystem Scale Module Provides Automated Weight-Based Dispensing with Managed Accountability
FDA Accepts New Drug Application (NDA) to review Midazolam Nasal Spray, an investigational product for the acute treatment of seizure clusters>
Midazolam Nasal Spray has been granted orphan drug designation by the United States Food and Drug Administration (US FDA) for the rescue treatment of seizures in patients who require control of intermittent bouts of increased seizure activity.
ElectroCore, Inc. Announces Research Collaboration with Massachusetts General Hospital to Explore Non-Invasive Vagus Nerve Stimulation in Neuroinflammation>
Non-invasive vagus nerve stimulation (nVNS) will be studied in preclinical settings, looking at the effects of this novel therapeutic approach on neuroinflammatory mechanisms which have been associated with conditions in the central nervous system (CNS) including pain, trauma and neurodegeneration.
Next Generation nVNS Therapy gammaCore Sapphire™ Now Available for Patients with Migraine and Episodic Cluster Headache in United States>
Innovative technology provides patients with convenient, easy-to-use treatment option without the potential side effects associated with commonly prescribed medicines
ElectroCore and UpScript Launch Program to Offer Direct-to-Patient Telemedicine Option for gammaCore™ in the United States>
gammaCore is the first FDA-cleared, nVNS therapy that can be self-administered by patients as needed for the acute treatment of pain associated with migraine and episodic cluster headache. UpScript offers a convenient way for prospective patients to consult with a licensed healthcare provider via telephone or video to find out if they are candidates for gammaCore.
Authors conclude novel delivery devices should be developed in conjunction with CAR-T therapies
VERASENSE™ Sensor-Assisted Technology Now Approved for Use with Zimmer Biomet Persona® Knee System, enabling surgeons to improve knee balance and customize implant position during surgery by using intraoperative sensor data.